Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
AGB101 Levetiracetam,
Mild Cognitive Impairment (Phase 3), Parkinson's Disease (Discontinued) AgeneBio, Inc. Amyloid-Related, Other Small Molecule Epilepsy and Partial Seizures in U.S., European Union, plus about 20 other countries
ALZT-OP1 Cromolyn sodium, Intal,
Alzheimer's Disease (Phase 3) AZTherapies, Inc. Amyloid-Related, Inflammation Small Molecule
AZD3293 LY3314814,
BACE inhibitor
Alzheimer's Disease (Phase 3) AstraZeneca, Eli Lilly & Co. Amyloid-Related Small Molecule
Aducanumab BIIB037 Alzheimer's Disease (Phase 3) Biogen Amyloid-Related Immunotherapy (passive)
Azeliragon PF-04494700 ,
Alzheimer's Disease (Phase 3) Pfizer, TransTech Pharma, Inc., vTv Therapeutics LLC Amyloid-Related, Inflammation Small Molecule
Crenezumab MABT5102A ,
Alzheimer's Disease (Phase 3) AC Immune SA, Genentech, Hoffmann-La Roche Amyloid-Related Immunotherapy (passive) None
Elenbecestat E2609,
BACE inhibitor
Alzheimer's Disease (Phase 3) Biogen, Eisai Co., Ltd. Amyloid-Related Small Molecule
Gantenerumab RO4909832,
Alzheimer's Disease (Phase 3) Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Amyloid-Related Immunotherapy (passive)
Solanezumab LY2062430 Alzheimer's Disease (Phase 3) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive) None
Verubecestat MK-8931, MK-8931-009 ,
BACE inhibitor
Alzheimer's Disease (Phase 3) Merck Amyloid-Related Small Molecule